^
    2d
    Combination therapy improves survival prognosis in anti-MDA5-antibody-positive dermatomyositis patients: a single-center retrospective study. (PubMed, Front Immunol)
    This study aimed to compare the efficacy and safety of calcineurin inhibitor monotherapy (CNI) versus combination therapy [CNI and tofacitinib (TOF) or cyclophosphamide (CTX)] as initial immunosuppressive regimens for MDA5+DM. In our study, combination therapy may improve survival prognosis in MDA5+ DM patients. Nevertheless, vigilant monitoring for opportunistic infections during treatment is essential.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8) • IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    cyclophosphamide • tofacitinib
    6d
    Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus (clinicaltrials.gov)
    P4, N=60, Recruiting, All India Institute of Medical Sciences, Bhubaneswar | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tofacitinib
    10d
    ODEN: Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Pfizer | Trial completion date: Aug 2026 --> Mar 2026 | Trial primary completion date: Aug 2026 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    tofacitinib
    15d
    KRXeljanzJIA: Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis (clinicaltrials.gov)
    P=N/A, N=375, Recruiting, Pfizer | Trial completion date: Jan 2027 --> Oct 2026 | Trial primary completion date: Jan 2027 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    tofacitinib
    16d
    EFFECT-1LAT: Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population (clinicaltrials.gov)
    P=N/A, N=4000, Not yet recruiting, Pfizer | Trial completion date: Oct 2025 --> Mar 2026 | Initiation date: Sep 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Mar 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    tofacitinib • Entyvio (vedolizumab) • Simponi (golimumab)
    18d
    TOFAST: Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)
    P=N/A, N=280, Recruiting, Pfizer | Trial completion date: Jun 2026 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    tofacitinib
    25d
    Consensus Virtual Screening and Ex Vivo Evaluation of Novel JAK2/STAT1,3 Inhibitors. (PubMed, ACS Omega)
    In the ex vivo evaluations, pitavastatin (0.5004 μM), eltrombopag (0.2548 μM), flavoxate (0.1536 μM), and empagliflozin (0.2548 μM) affected the phosphorylation of downstream STAT1 and STAT3 signaling molecules, similarly to tofacitinib citrate (TOF) (1.2 nM ). These results encourage further in-depth preclinical experiments aimed at exploring the additional effects of the JAK2-STAT1/3 signaling pathway.
    Preclinical • Journal
    |
    JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    Promacta (eltrombopag) • tofacitinib • pitavastatin
    25d
    Efficacy of Tofacitinib in Refractory Axial Spondylarthritis: A Dose-Escalation Study. (PubMed, Cureus)
    Conclusions In patients not meeting 12-week targets on 10 mg, escalation to 15 mg yielded additional clinically meaningful improvement with a safety profile generally comparable to 10 mg. Selective escalation may be a feasible treat-to-target strategy where alternatives are limited.
    Journal
    |
    CRP (C-reactive protein)
    |
    tofacitinib
    1m
    The efficacy and safety of the combination of Anti-inflammation Treatment (Hirudoid introduction followed by yellow light therapy) and oral tofacitinib versus oral tofacitinib alone in the treatment of mild to moderate erythematotelangiectatic rosacea in Chinese adults : A prospective parallel controlled single-blind cohort study (ChiCTR2500111274)
    P4, N=92, Not yet recruiting, The Fourth Affiliated Hospital Zhejiang University School of Medicine; The Fourth Affiliated Hospital Zhejiang University School of Medicine
    New P4 trial
    |
    tofacitinib
    1m
    Efficacy and Safety of Tofacitinib versus Glucocorticoids in Patients with Active Segmental Vitiligo: A 72-Week, Single-Center, Parallel-Control, Open-Label, Randomized Extension Trial (ChiCTR2500111079)
    P=N/A, N=152, Not yet recruiting, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China; Department of Dermatology, Huashan Hospital, Fudan University, Shangha
    New trial
    |
    tofacitinib
    1m
    Clinical study of JAK inhibitors in the treatment of rosacea with erythematotelangiectatic rosacea (ChiCTR2500109214)
    P=N/A, N=84, Not yet recruiting, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    tofacitinib
    1m
    A single-center exploratory study on the efficacy and safety of tetrandrine tablets in the treatment of interstitial lung disease associated with rheumatoid arthritis (ChiCTR2500107574)
    P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hos
    New trial
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • tofacitinib • CBT-1 (tetrandrine)